17/05/2024
Chiesi to Present Data at the American Thoracic Society Conference
17/05/2024
Chiesi to Present Data at the American Thoracic Society Conference
10/05/2024
Empowering Diversity & Inclusion: Chiesi Affinity Networks
10/05/2024
Empowering Diversity & Inclusion: Chiesi Affinity Networks
02/05/2024
Chiesi Farmaceutici S.p.A. has obtained ISO 37001:2016 certification for its Anti-Bribery Management System
02/05/2024
Chiesi Farmaceutici S.p.A. has obtained ISO 37001:2016 certification for its Anti-Bribery Management System
12/03/2024
Chiesi Achieves Platinum Medal from EcoVadis
12/03/2024
Chiesi Achieves Platinum Medal from EcoVadis
17/05/2024
Chiesi to Present Data at the American Thoracic Society Conference
Eight abstracts from Chiesi’s global respiratory research portfolio will be presented at the American Thoracic Society (ATS) 2024 International Conference in San Diego starting from May 17, 2024. Presentations include preclinical and clinical stage global studies in asthma, Chronic Obstructive Pulmonary Disease (COPD) and other respiratory conditions. “Chiesi’s Air franchise has a robust history spanning multiple decades of delivering innovative medicines in Europe, and we’re excited to share some of the research supporting our global scientific advancements in the respiratory therapeutic area at ATS," said Carmen Dell’Anna, Head of Global Medical Affairs, Chiesi Group. "Alongside updates on our scientific progress, the Chiesi expert-led Innovation Hub will focus on discussing the role of small airway dysfunction and persistent airflow limitation in asthma. With a solid presence at the ATS conference this year, we affirm our distinctive commitment to address respiratory-related burdens by focusing on creating shared value for people and the planet.” Demonstrating the company’s commitment to innovation, Chiesi is a Sapphire level sponsor of the annual ATS Research Program Benefit. Chiesi is also sponsoring a one-year research grant for a respiratory disease researcher to advance the understanding of obstructive lung disease. Chiesi Foundation will also participate in the conference with a session titled "Global Health Inequities in Chronic Respiratory Disease: Challenges and Potential Solutions." Chaired by Dr. Mario Scuri, MD, PhD, GASP Technical Advisor at Chiesi Foundation, the session will feature renowned speakers, including Dr. William Checkley, Dr. Laura Nicolaou, and Dr. Robert D. Levy. Chiesi’s US respiratory business continues growing since, on May 6, 2024, it signed a license agreement with Gossamer Bio to develop and commercialize seralutinib. The collaboration leverages Chiesi's leadership in inhaled drugs and Gossamer Bio's expertise in pulmonary hypertension with the goal of addressing conditions with high unmet medical need.
10/05/2024
Empowering Diversity & Inclusion: Chiesi Affinity Networks
At Chiesi, we aim to create an inclusive environment and foster a culture where everybody feels valued, respected, and empowered to freely express themselves, making our Company #ThePlaceToBe. This goal is attainable thanks to the guidance of our Global D&I Vision and Strategy and the support of our D&I Committee that have launched a new initiative called Chiesi Affinity Networks (CANs). CANs are Employee Resource Groups (ERGs), employee-led initiatives aimed at fostering diversity and inclusivity within the workplace. They create a sense of belonging, encourage dialogue, and play a crucial role in shaping an environment where employees feel safe to be themselves, fostering high-trust relationships crucial for innovation. CANs are indeed volunteer-led groups coming together under the name of a common affinity, cause, or theme, to represent invisible needs and provide a space for discussion, ideas and concrete solutions for Chiesi. We already have several active CANs in Chiesi, discover them all! Chiesi Existing CANs: GOALS: To be a visible and accessible resource for all employees and to be a tool for the continuous improvement of the work environment by pursuing education and awareness initiatives on LGBTQ+ issues in the company. Contribute to cultivating a deeper understanding of diverse cultures, fostering the internationalization of the way we work and collaborate. By learning to implement the strengths inherent in each cultural perspective, we aim to optimize our collective endeavors. Cultivate a mindset shift in how individuals perceive their own abilities and disabilities by encouraging them to view challenges or limitations as opportunities for adaptation. The aim is to promote inclusivity and a greater appreciation for one’s diverse capabilities. Promote awareness of generational diversity, create and support a diversified group thanks to the contribution of different generations by sharing experiences and fostering creativity, motivation, and ambition. Give visibility to the peculiarity of different lifestyles, the values they generate, the challenges and the needs they have, proposing actions to improve Mental Health. Connect and support women in Chiesi, fostering gender empowerment through communication campaigns, education programs and the celebration of some international days.
02/05/2024
Chiesi Farmaceutici S.p.A. has obtained ISO 37001:2016 certification for its Anti-Bribery Management System
Chiesi Farmaceutici S.p.A. has obtained ISO 37001:2016 certification for its Anti-Bribery Management System Over 70 people involved, more than 20 departments that contributed, ten months of work: these are the numbers behind Chiesi certification. This certification, obtained through the collaboration of a dedicated cross-functional team, confirms Chiesi’s commitment to operate in accordance with the highest compliance standards and ethical behaviors. It is also a recognition of the robustness of the anti-bribery system implemented by the Company and the high level of awareness of its collaborators. Having a structured and certified anti-bribery management system enables the definition and maintenance of a harmonized set of controls designed to prevent, detect and address bribery systematically and on a large scale, thereby creating efficiencies and fostering a culture of anti-bribery compliance. “This certification is a great achievement and an incredible business opportunity, also considering its transversal nature and its ability to create cross-functional links and pool efforts. It demonstrates once again Chiesi's commitment to act in accordance with the sustainability values and confirms the central role that compliance plays in every business process and relations with business partners and stakeholders.” - Valentina Fanelli, Global Ethics, Transparency and Anti-Bribery Compliance Officer Information about ISO 37001:2016: The ISO 37001:2016 is an international standard published by ISO (International Organization for Standardization) in 2016 that companies can use to implement and certify their anti-bribery management system, which is designed to prevent, detect, and respond to bribery. The ISO 37001:2016 standard reflects international good practice and can be used in all jurisdictions.
12/03/2024
Chiesi Achieves Platinum Medal from EcoVadis
As a testament to its steadfast commitment to sustainability, Chiesi proudly announces its achievement of the Platinum medal from EcoVadis, with a score of 78/100. This important recognition places the company among the top percentage of organizations assessed by Ecovadis. EcoVadis Platinum Medals are assigned to enterprises that have not only completed the rigorous assessment process but have also demonstrated exceptional management systems that address sustainability criteria outlined by the organization. To be eligible for such recognition, companies must excel across four key themes: Environment, Ethics, Labor & Human Rights, and Sustainable Procurement. Chiesi's attainment of the Platinum medal from EcoVadis is not just a recognition of its achievements but a testament to its ongoing commitment to shaping a more sustainable future for all. Through continued collaboration with its partners and suppliers, the biopharmaceutical Group will keep supporting a journey of mutual learning and co-evolution of the whole ecosystem. "Engaging in dialogue and sharing values with our partners enable us to tackle the social challenges and business opportunities together, combining corporate success with social progress. Respect for human rights and the fight against climate change are among the most urgent global questions – affirmed Guido D’Agostino, Head of Global Procurement at Chiesi Group -. To reach our goals we have set ourselves, the contributions and collaboration of all our suppliers and strategic partners are needed, since they play a key role in the evolution of Chiesi's Value Chain." About EcoVadis: EcoVadis stands as a leading global platform for assessing and rating companies based on their environmental, social, and ethical performance. Its rigorous methodology, rooted in international sustainability standards, evaluates the integration of Sustainability/CSR principles into companies' business and management systems across various industries and regions.
08/03/2024
Chiesi’s investment in women equal pay achieves the Fair Pay certification
On this International Women's Day Chiesi joins the commitment of the UN for 2024, "Invest in Women: Accelerate Progress," and proudly announces a significant milestone in its dedication to gender equality. The international biopharmaceutical Group has received top-level certification from the Fair Pay Innovation Lab, a renowned organization for fair pay, for successfully reducing the Gender Pay Gap to below 1%. This accomplishment highlights Chiesi's dedication to fostering an inclusive workplace where every employee is respected and fairly compensated for their contributions. Our journey towards equality has been guided by a holistic approach. We've implemented two merit-based pay cycles, ensuring that recognition is solely based on performance and skills, regardless of gender. Additionally, we've carefully reviewed our HR processes to root out any biases that could lead to unequal pay. In addition to these actions, Chiesi places a strong emphasis on advancing women into senior positions within the organization. By actively identifying and supporting talented women, the Group not only diversifies its leadership team but also establishes role models and mentors for future generations of female professionals. This diversity of perspectives fosters innovation and propels progress across industries, contributing to the competitiveness of businesses and economies in an increasingly interconnected world. The attainment of Universal Fair Pay Leader status signifies Chiesi's transparent commitment to fair pay practices, inclusive hiring and promotion procedures, reconciliation measures, and organizational culture. As we mark this milestone on International Women's Day, let it be a reminder of our ongoing journey towards a future where equality isn't just a goal but a reality for all.
12/02/2024
Empowering Women in Science and Healthcare: Chiesi’s Commitment to Gender Equality
In 1936, Neive Terzi became the first female researcher hired at Chiesi, a year after the company was founded as a pioneer in the healthcare field. Not only was she the first employee with a degree at the time, but she laid the foundation of a journey of women empowerment that has become deeply ingrained in Chiesi's DNA. Of more than 6,500 employees worldwide, today 55% are women, this figure climbs even higher in the Research and Development department, where 65% of over 650 researchers are women. These numbers are a testament to Chiesi’s dedication to inclusivity but also reflects a global trend that calls for greater representation of women in scientific fields. According to the United Nations, female researchers typically tend to have shorter, lower paid careers. While they represent 33.3% of all researchers, only 12% of members of national science academies are women.[1] In light of these challenges, Chiesi is resolute in its mission to address these disparities head-on and create a workplace where all employees can thrive, regardless of gender. Through equal opportunities initiatives, fair compensation, and supportive policies, the Group aims to create an environment where every employee feels valued, respected, and fairly rewarded. Challenging Ourselves to Go Beyond In 2021, Chiesi embarked on a global challenge to tackle gender disparities within the organization. Despite already maintaining a low Group Unexplained Pay Gap of -1.48%, the Group sought to surpass industry benchmarks by reducing the Gender Pay Gap even further. By 2022, one year ahead of the expected timeline, Chiesi was able to achieve its goal of reducing the Gender Pay Gap to below 1%, through rigorous efforts, including two merit pay cycles, a round of pay equity adjustments, a comprehensive review of HR processes, and targeted recruitment of women in senior roles. Today, Chiesi Group is proud to announce that its Gender Pay Gap has narrowed to -0.77% at the Group level, in line with the international targets. While the unexplained gender pay gap varies from country to country, it is statistically non-significant in most regions. Not Just Words: Gender Equality Certification As a testament to its steadfast commitment, Chiesi has also confirmed the Gender Equality Certification from Bureau Veritas, in accordance with Italian law UNI/PdR 125:2022. This certification involved both Chiesi Farmaceutici and Chiesi Italia and encompasses all six indicator areas (KPIs) outlined by the guidelines: culture and strategy, governance, HR processes, opportunities for growth and inclusion of women in the company, gender pay equality, parental protection, and work-life balance. By empowering women in science and healthcare, Chiesi is driving innovation, inspiring future generations, and ensuring that diverse voices and perspectives are at the forefront of scientific advancements. [1] https://www.un.org/en/observances/women-and-girls-in-science-day